MCID: ATS171
MIFTS: 17

Autism 9

Categories: Genetic diseases, Rare diseases, Mental diseases

Aliases & Classifications for Autism 9

MalaCards integrated aliases for Autism 9:

Name: Autism 9 54 29

Classifications:



External Ids:

OMIM 54 611015

Summaries for Autism 9

OMIM : 54
Autism, the prototypic pervasive developmental disorder (PDD), is usually apparent by 3 years of age. It is characterized by a triad of limited or absent verbal communication, a lack of reciprocal social interaction or responsiveness, and restricted, stereotypic, and ritualized patterns of interests and behavior (Bailey et al., 1996; Risch et al., 1999). 'Autism spectrum disorder,' sometimes referred to as ASD, is a broader phenotype encompassing the less severe disorders Asperger syndrome (see ASPG1; 608638) and pervasive developmental disorder, not otherwise specified (PDD-NOS). 'Broad autism phenotype' includes individuals with some symptoms of autism, but who do not meet the full criteria for autism or other disorders. Mental retardation coexists in approximately two-thirds of individuals with ASD, except for Asperger syndrome, in which mental retardation is conspicuously absent (Jones et al., 2008). Genetic studies in autism often include family members with these less stringent diagnoses (Schellenberg et al., 2006). For a discussion of genetic heterogeneity of autism, see 209850. (611015)

MalaCards based summary : Autism 9 An important gene associated with Autism 9 is MET (MET Proto-Oncogene, Receptor Tyrosine Kinase). The drugs Adrenergic Agents and Atomoxetine Hydrochloride have been mentioned in the context of this disorder. Affiliated tissues include brain.

Related Diseases for Autism 9

Diseases in the Autism Spectrum Disorder family:

Autism 19 Autism 9
Autism 10 Autism 18

Symptoms & Phenotypes for Autism 9

Clinical features from OMIM:

611015

Drugs & Therapeutics for Autism 9

Drugs for Autism 9 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 71)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1 Adrenergic Agents Phase 4
2 Atomoxetine Hydrochloride Phase 4
3 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
4 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3
5
Dopamine Approved Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
6
Fluoxetine Approved, Vet_approved Phase 3,Phase 2 54910-89-3 3386
7
Metformin Approved Phase 3 657-24-9 14219 4091
8
Adenosine Approved, Investigational Phase 2, Phase 3 58-61-7 60961
9
Diphenhydramine Approved Phase 2, Phase 3 58-73-1, 147-24-0 3100
10
Methylphenidate Approved, Investigational Phase 2, Phase 3 113-45-1 4158
11
Promethazine Approved Phase 2, Phase 3 60-87-7 4927
12
Risperidone Approved, Investigational Phase 2, Phase 3,Phase 1 106266-06-2 5073
13
Melatonin Approved, Nutraceutical, Vet_approved Phase 2, Phase 3,Phase 1 73-31-4 896
14 Antipsychotic Agents Phase 3,Phase 1
15 Central Nervous System Depressants Phase 3,Phase 2,Phase 1
16 Dopamine Agents Phase 3,Phase 2,Phase 1
17 Dopamine Antagonists Phase 3,Phase 1
18 Dopamine D2 Receptor Antagonists Phase 3
19 Paliperidone Palmitate Phase 3
20 Psychotropic Drugs Phase 3,Phase 2,Phase 1
21
Serotonin Phase 3,Phase 1 50-67-9 5202
22 Serotonin 5-HT2 Receptor Antagonists Phase 3
23 Serotonin Agents Phase 3,Phase 1
24 Serotonin Antagonists Phase 3,Phase 1
25 Tranquilizing Agents Phase 3,Phase 2,Phase 1
26 Antidepressive Agents Phase 3
27 Antidepressive Agents, Second-Generation Phase 3
28 Cytochrome P-450 CYP2D6 Inhibitors Phase 3
29 Cytochrome P-450 Enzyme Inhibitors Phase 3
30 Serotonin Uptake Inhibitors Phase 3
31 Hypoglycemic Agents Phase 3
32 Pharmaceutical Solutions Phase 3,Phase 2,Phase 1
33 Adrenergic beta-Antagonists Phase 2, Phase 3
34 Antioxidants Phase 2, Phase 3,Phase 1
35 Lithium carbonate Phase 2, Phase 3 554-13-2
36 Protective Agents Phase 2, Phase 3,Phase 1
37
Succimer Approved Phase 1, Phase 2 304-55-2 9354
38
Memantine Approved, Investigational Phase 2 19982-08-2 4054
39
Everolimus Approved Phase 2 159351-69-6 6442177
40
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
41
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
42
Dronabinol Approved, Illicit Phase 2 1972-08-3 16078 2978
43
Acetylcysteine Approved, Investigational Phase 2 616-91-1 12035
44 Antidotes Phase 1, Phase 2
45 Chelating Agents Phase 1, Phase 2
46 Antiparkinson Agents Phase 2
47 Excitatory Amino Acid Antagonists Phase 2
48 Excitatory Amino Acids Phase 2
49 Anti-Bacterial Agents Phase 2
50 Antibiotics, Antitubercular Phase 2

Interventional clinical trials:

(show all 49)

id Name Status NCT ID Phase Drugs
1 Atomoxetine, Placebo and Parent Management Training in Autism Completed NCT00844753 Phase 4 atomoxetine;Placebo
2 Atomoxetine Versus Placebo for Symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents With Autism Spectrum Disorder Completed NCT00380692 Phase 4 Atomoxetine;Placebo
3 A Study of Atomoxetine for Attention Deficit and Hyperactive/Impulsive Behaviour Problems in Children With ASD Completed NCT00485849 Phase 4 Atomoxetine Hydrochloride
4 Study of Paliperidone ER in Adolescents and Young Adults With Autism Completed NCT00549562 Phase 3 Paliperidone ER
5 Supporting the Well Being of Families of Young Children With Autism Spectrum Disorders Completed NCT01021384 Phase 3
6 Study of Fluoxetine in Autism Completed NCT00515320 Phase 3 Fluoxetine;Placebo
7 Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorders (ASD) Completed NCT01825798 Phase 3 Metformin;Placebo
8 Understanding Sleep Problems in Children With Autism Spectrum Disorder Completed NCT00691080 Phase 2, Phase 3
9 Randomized Controlled Trial of Acupuncture Versus Sham Acupuncture in Autistic Spectrum Disorder Completed NCT00352248 Phase 3
10 Dimercaptosuccinic Acid (DMSA) Treatment of Children With Autism and Heavy Metal Toxicity Completed NCT00811083 Phase 1, Phase 2 DMSA - dimercaptosuccinic acid
11 Targeting GABA-A for the Treatment of Social Disability in Young Adults With Autism Spectrum Disorders: A Phase II Proof of Mechanism Trial Completed NCT01966679 Phase 2 AZD7325;Placebo
12 A Multi-site Double-blind Placebo-controlled Trial of Memantine Versus Placebo in Children With Autism (MEM) Completed NCT01372449 Phase 2 Memantine;Placebo
13 A Study of Pregnenolone in the Treatment of Individuals With Autism Completed NCT01881737 Phase 2 Pregnenolone
14 Trial of RAD001 and Neurocognition in Tuberous Sclerosis Complex (TSC) Completed NCT01289912 Phase 2 RAD001
15 Cannabinoids for Behavioral Problems in Children With ASD Recruiting NCT02956226 Phase 2 Cannabinoids - 99% pure cannabinoids mix;Placebo;Cannabinoids - whole plant extract
16 Road to Discovery for Combination Probiotic BB-12 With LGG in Treating Autism Spectrum Disorder Recruiting NCT02674984 Phase 1, Phase 2 BB-12 with LGG;Placebo
17 Essential Oils for Enhancing QOL in ASD Recruiting NCT02543203 Phase 2
18 Pilot Trial of Pregnenolone in Autism Recruiting NCT02627508 Phase 2 Pregnenolone;Placebo
19 A Feasibility Study of N-acetylcysteine for Self-injurious Behavior in Children With Autism Spectrum Disorder Not yet recruiting NCT03008889 Phase 2 N-acetylcysteine;Placebo
20 Omega-3 Fatty Acids Monotherapy in Children and Adolescents With Autism Spectrum Disorders Terminated NCT01248130 Phase 2 Omega-3 Fatty Acid
21 A Study of Divalproex Sodium in Children With ASD and Epileptiform EEG Withdrawn NCT01170325 Phase 2 Divalproex Sodium;Placebo Comparator
22 Melatonin for Sleep in Children With Autism Completed NCT00927030 Phase 1 supplemental liquid melatonin;flavored liquid or liquid supplemental melatonin
23 A Study of RO5028442 in Adult Male High-Functioning Autistic Patients Completed NCT01474278 Phase 1 Placebo;RO5028442
24 Risperidone Pharmacokinetics in Children With Pervasive Developmental Disorder (PDD) Completed NCT00147394 Phase 1 Risperidone
25 Oxytocin in Spectrum Autism Disorders Recruiting NCT03183674 Phase 1 Oxytocin
26 Equine-assisted Occupational Therapy for Children With Autism Spectrum Disorder Completed NCT02714101
27 Study to Evaluate the Janssen Autism Knowledge Engine in Children and Adults With Autism Spectrum Disorder Completed NCT02299700 Early Phase 1
28 A Study to Assess the Role of a Gluten Free-dairy Free (GFCF) Diet in the Dietary Management of Autism Associated Gastrointestinal Disorders Completed NCT01116388
29 Comparing Parent-Implemented Interventions for Toddlers With Autism Spectrum Disorders Completed NCT00760812
30 Social Skills in Children With Autism Spectrum Disorders Completed NCT02147236
31 Social ABCs for Toddlers With Signs of Autism Spectrum Disorder: Trial of a Parent-Mediated Intervention Completed NCT02428452
32 A Collaborative Public/Private Employment Training and Placement Model ASD Transition Age Youth With Autism Spectrum Disorder (ASD) Completed NCT02360332
33 A Bicycle Training Intervention Completed NCT02046889
34 Study to Assess the Janssen Autism Knowledge Engine in Participants With Autism Spectrum Disorder and in a Normally Developing Cohort Completed NCT02668991 Early Phase 1
35 The Role of Brain-derived Neurotropic Factor in the Relationship Between Executive Function and Physical Training Completed NCT02503579
36 Phenotypic and Genotypic Studies in Congenital and Early Onset Ataxias Completed NCT01488461
37 Technology-supported Behavioral Feeding Intervention Completed NCT02119910
38 Changing Developmental Trajectories Through Early Treatment Recruiting NCT01985022
39 Efficacy of IMPACT in Infant Siblings of Children With ASD Recruiting NCT03274622
40 Pilot Trial of a Social Skills Group Treatment (Secret Agent Society Program) Recruiting NCT02574273
41 Evaluation of Social ABCs With Attention Training Intervention for Toddlers With Suspected Autism Recruiting NCT03215394
42 Online Study of Individuals With Genetic Changes and Features of Autism: Simons Variation in Individuals Project (Simons VIP) Recruiting NCT01238250
43 Brain-Computer Interface-based Programme for the Treatment of ASD/ADHD Recruiting NCT02618135
44 Family Networks (FaNs) for Children With Developmental Disorders and Delays Recruiting NCT02792894
45 Mirror Neuron Network Dysfunction as an Early Biomarker of Neurodevelopmental Disorder Recruiting NCT03307317
46 Mobilizing Community Systems to Engage Families in Early Autism Spectrum Disorder (ASD) Detection & Services Enrolling by invitation NCT02445105
47 Promoting Transactional Supports to Optimize Social Communication Outcomes for Infants and Their Families Not yet recruiting NCT03307057
48 KONTAKT Australia a Social Skills Group Training for Adolescents on the Autism Spectrum Not yet recruiting NCT03294668
49 Trial of Propranolol in Adults and Adolescents With ASD and Predictors of Response Withdrawn NCT02414451 Propranolol;Placebo

Search NIH Clinical Center for Autism 9

Genetic Tests for Autism 9

Genetic tests related to Autism 9:

id Genetic test Affiliating Genes
1 Autism 9 29

Anatomical Context for Autism 9

MalaCards organs/tissues related to Autism 9:

39
Brain

Publications for Autism 9

Variations for Autism 9

Expression for Autism 9

Search GEO for disease gene expression data for Autism 9.

Pathways for Autism 9

GO Terms for Autism 9

Sources for Autism 9

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....